Summarized by Masters of Longevity from Startupticker.ch.
Collaborations advanced PLT012, ADC discovery and a Phase 3 Fabry trial.
Key Takeaways
- Pilatus has dosed the first patient in Hong Kong.
- Alentis has in-licensed ADC linkers and payloads from PinotBio.
- Idorsia has initiated a Phase 3 lucerastat study and received CHF 7 million.
